A phospholipid complex to improve the oral bioavailability of XXXX .

@entity15605 @entity6188 @entity4212 @entity58010 @entity3088 @entity10333 @entity35 @entity3092
AIM: A phospholipid complex (TFH-PC) was prepared to increase the oral bioavailability of @entity58010 , @entity15605 , and @entity3092 from TFH (total @entity4212 of Hippophae rhamnoides L.). METHODS: Solvent evaporation was used to prepare TFH-PC. Relevant parameters were investigated based on the complexation rate of @entity58010 , @entity15605 , and @entity3092 . Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), X-ray power diffraction (X-RPD), and scanning electron microscopy (SEM) were used for characterization. Solubility, @entity10333 -water partition coefficient (log P), dissolution rate, and in vivo pharmacokinetics were also investigated. RESULTS: TFH-PC was successfully prepared in @entity6188 with a drug to phospholipid ratio of 1:1, reaction temperature of 20     C, and a reaction time of 1   h. The complexation rates of @entity58010 , @entity15605 , and @entity3092 were 97.7%, 95.97%, and 92.23%, respectively. FT-IR, DSC, X-RPD, and SEM confirmed the formation of TFH-PC. The aqueous solubilities of the three @entity3088 in TFH-PC increased 22.0-26.8-fold compared with TFH. The dissolution of @entity58010 , @entity15605 , and @entity3092 in TFH-PC was 84.32%, 90.77%, and 100% within 10   min, respectively, greatly improved over TFH. After oral administration of TFH-PC in @entity35 , the bioavailability of @entity58010 , @entity15605 , and @entity3092 in TFH-PC relative to TFH was 223%, 172%, and 242%, respectively. CONCLUSION: The oral absorption of @entity58010 , @entity15605 , and @entity3092 was significantly improved in TFH-PC, mainly due to increased solubility and dissolution rate. This phospholipid complex shows potential for oral delivery of the @entity3088 in TFH.
